AUPH: Aurinia Pharmaceuticals Inc
Performance
AUPH +13.76%
Watchlist
Select an item
Summary
AUPH at a glance
AUPH returned +13.76% over the past year and -12.24% a year over five years. Its worst drop in that year was -21.75%, smaller than 76% of stocks on Redstone, and its Sharpe ratio of 0.44 beats 47% of stocks on Redstone. It pays no dividends.
Current Drawdown
-10.74%
Rolling Volatility
33.92%
Actions
Metrics
Risk Indicators
Alpha9.03%
Beta0.67x
Sharpe0.44
Sortino0.64
Omega1.08
Calmar0.63
Martin1.53
Profile
About AUPH
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.2B
- Listed
- Oct 2009
- Employees
- 128
- Headquarters
- Edmonton, A0
- Website
- auriniapharma.com
Comparisons